Document:

Exhibit 10.4

 

REGISTRATION RIGHTS AGREEMENT

 

THIS REGISTRATION RIGHTS AGREEMENT
(this “Agreement”), dated as of [●], 2022, is made and entered into by and among:

 

(i)   Biolog-id,
a French société anonyme registered with the French Registry of commerce and companies under number 481 216 430 R.C.S.
Nanterre (the “Company”);

 

(ii)   the
equityholders of Genesis Growth Tech Acquisition Corp., a Cayman Islands exempted company (the “SPAC”), designated
on Schedule A hereto as SPAC Holders, that will receive Ordinary Shares (as defined below) pursuant to the transactions contemplated
by the Business Combination Agreement (as defined below) (the “SPAC Holders”); and

 

(iii)   the
equityholders of the Company designated on Schedule B hereto as Biolog Equityholders (collectively, the “Biolog Equityholders”
and, together with the SPAC Holders and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 5.2
of this Agreement, a “Holder” and collectively the “Holders”).

 

RECITALS

 

WHEREAS, pursuant to
that certain Business Combination Agreement, dated as of [●], 2022 (as it may be amended, supplemented, restated or otherwise modified
from time to time, the “Business Combination Agreement”), by and among the Company and the SPAC, the SPAC will
merge with and into the Company with the Company continuing as the surviving entity (the “Merger”); and

 

WHEREAS, in connection
with the consummation of the transactions described above (the “Transactions”), the Company and the Holders
desire to enter into this Agreement, pursuant to which the Company shall grant the Holders certain registration rights with respect to
the Registrable Securities (as defined below) on the terms and conditions set forth in this Agreement.

 

NOW, THEREFORE,
in consideration of the representations, covenants and agreements contained herein, and certain other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

 

ARTICLE
I

DEFINITIONS

 

1.1   Definitions.
The terms defined in this Article I shall, for all purposes of this Agreement, have the respective meanings set forth below:

 

“Action”
means any claim, action, suit, audit, examination, assessment, arbitration, mediation or inquiry, or any proceeding or investigation,
by or before any Governmental Authority.

 

“ADS”
means an American Depositary Share representing one Ordinary Share.

 

“Adverse Disclosure”
shall mean any public disclosure of material non-public information, which disclosure, in the good faith judgment of the Chief Executive
Officer of the Company or the Board, after consultation with counsel to the Company, (i) would be required to be made in any Registration
Statement or Prospectus in order for the applicable Registration Statement or Prospectus not to contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements contained therein (in the case of any prospectus and any preliminary
prospectus, in the light of the circumstances under which they were made) not misleading, (ii) would not be required to be made at such
time if the Registration Statement were not being filed, declared effective or used, as the case may be, and (iii) the Company has a bona
fide business purpose for not making such information public.

 

“Agreement”
shall have the meaning given in the Preamble hereto.

 

     

     

    

 

“Biolog Equityholders”
shall have the meaning given in the Preamble hereto.

 

“Block Trade”
shall have the meaning given in Section 2.4.1.

 

“Board”
means the board of directors of the Company.

 

“Business Combination
Agreement” shall have the meaning given in the Recitals hereto.

 

“Closing Date”
shall have the meaning given in the Business Combination Agreement.

 

“Closing”
shall have the meaning given in the Business Combination Agreement.

 

“Commission”
shall mean the Securities and Exchange Commission.

 

“Company”
shall have the meaning given in the Preamble hereto and includes the Company’s successors by recapitalization, merger, consolidation,
spin-off, reorganization or similar transaction.

 

“Demanding Holder”
shall have the meaning given in Section 2.1.4.

 

“Exchange Act”
shall mean the Securities Exchange Act of 1934, as it may be amended from time to time.

 

“FINRA”
shall mean the Financial Industry Regulatory Authority Inc.

 

“Form F-1 Shelf”
shall have the meaning given in Section 2.1.1.

 

“Form F-3 Shelf”
shall have the meaning given in Section 2.1.1.

 

“Governmental
Authority” means any federal, state, provincial, municipal, local or foreign government, governmental authority, regulatory
or administrative agency (which for the purposes of this Agreement shall include FINRA and the Commission), governmental commission, department,
board, bureau, agency or instrumentality, court or tribunal.

 

“Governmental
Order” means any order, judgment, injunction, decree, writ, stipulation, determination or award, in each case, entered by
or with any Governmental Authority.

 

“Holder Information”
shall have the meaning given in Section 4.1.2.

 

“Holders”
shall have the meaning given in the Preamble hereto, for so long as such person or entity holds any Registrable Securities.

 

“Law”
means any statute, law, ordinance, rule, regulation or Governmental Order, in each case, of any Governmental Authority.

 

“Lockup Agreement”
shall mean the Confidentiality and Lockup Agreement, dated as of [●], 2022, by and among the Company and the other parties thereto,
as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time.

 

“Lock-Up Period”
shall have the meaning given in the Lockup Agreement.

 

“Maximum Number
of Securities” shall have the meaning given in Section 2.1.5.

 

“Merger”
shall have the meaning given in the Recitals hereto.

 

“Minimum Takedown
Threshold” shall have the meaning given in Section 2.1.4.

 

    2

     

    

 

“Misstatement”
shall mean an untrue statement of a material fact or an omission to state a material fact required to be stated in a Registration Statement
or Prospectus or necessary to make the statements in a Registration Statement or Prospectus, (in the case of a Prospectus, in the light
of the circumstances under which they were made) not misleading.

 

“Ordinary Shares”
shall mean the ordinary shares of the Company, no par value.

 

“Permitted Transferees”
shall mean any person or entity to whom a Holder of Registrable Securities is permitted to transfer such Registrable Securities prior
to the expiration of the Lock-up Period pursuant to the Lockup Agreement.

 

“Piggyback Registration”
shall have the meaning given in Section 2.2.1.

 

“Plan of Distribution”
shall have the meaning given in Section 2.2.1.

 

“Prospectus”
shall mean the prospectus included in any Registration Statement, as supplemented by any and all prospectus supplements and as amended
by any and all post-effective amendments and including all material incorporated by reference in such prospectus.

 

“Registrable Security”
shall mean (a) any outstanding Ordinary Shares or other equity security held by a Holder immediately following the Closing (including
ADSs representing such Ordinary Shares or Ordinary Shares issued or issuable upon the conversion of such equity security) or received
pursuant to the Transaction contemplated by the Business Combination Agreement, (b) any Ordinary Shares (including ADSs representing such
Ordinary Shares) otherwise acquired or owned by a Holder following the date hereof to the extent that such securities are “restricted
securities” (as defined in Rule 144) or are otherwise held by an “affiliate” (as defined in Rule 144) of the Company
and for so long as the Holder may be deemed to be an Underwriter pursuant to Rule 145(c), and (d) any other equity security of the Company
or any of its subsidiaries issued or issuable with respect to any securities referenced in clause (a) or (b) above by way of a stock dividend
or stock split or in connection with a recapitalization, merger, consolidation, spin-off, reorganization or similar transaction; provided,
however, that, as to any particular Registrable Security, such securities shall cease to be Registrable Securities upon the earliest
to occur of: (A) a Registration Statement with respect to the sale of such securities shall have become effective under the Securities
Act and such securities shall have been sold, transferred, disposed of or exchanged in accordance with such Registration Statement by
the applicable Holder; (B) such securities shall have ceased to be outstanding; (C) such securities may be sold without registration pursuant
to Rule 144 or any successor rule promulgated under the Securities Act (but with no requirement to maintain current public information
or volume or other restrictions or limitations including as to manner or timing of sale); and (D) such securities have been sold to, or
through, a broker, dealer or underwriter in a public distribution or other public securities transaction.

 

“Registration”
shall mean a registration, including any related Shelf Takedown, effected by preparing and filing a registration statement, prospectus
or similar document in compliance with the requirements of the Securities Act, and the applicable rules and regulations promulgated thereunder,
and such registration statement becoming effective.

 

“Registration
Expenses” shall mean the expenses of Registration, including, without limitation, the following:

 

(A)   all
registration and filing fees (including fees with respect to filings required to be made with the Financial Industry Regulatory Authority,
Inc.) and fees of any national securities exchange on which the Ordinary Shares are then listed;

 

(B)   fees
and expenses of compliance with securities or blue sky laws (including reasonable fees and disbursements of outside counsel for the Underwriters
in connection with blue sky qualifications of Registrable Securities);

 

(C)   printing,
messenger, telephone and delivery expenses;

 

    3

     

    

 

(D)   reasonable
fees and disbursements of counsel for the Company;

 

(E)   reasonable
fees and disbursements of all independent registered public accountants of the Company incurred specifically in connection with such Registration;
and

 

(F)   reasonable
fees and expenses of one legal counsel selected by the majority-in-interest of the securities requested to be registered by the Demanding
Holders in an Underwritten Offering.

 

“Registration
Statement” shall mean any registration statement that covers Registrable Securities pursuant to the provisions of this Agreement,
including the Prospectus included in such registration statement, amendments (including post-effective amendments) and supplements to
such registration statement, and all exhibits to and all material incorporated by reference in such registration statement.

 

“Requesting Holders”
shall have the meaning given in Section 2.1.5.

 

“Securities Act”
shall mean the Securities Act of 1933, as amended from time to time.

 

“Shelf”
shall mean the Form F-1 Shelf, the Form F-3 Shelf or any Subsequent Shelf Registration, as the case may be.

 

“Shelf Registration”
shall mean a registration of securities pursuant to a registration statement filed with the Commission in accordance with and pursuant
to Rule 415 promulgated under the Securities Act (or any successor rule then in effect).

 

“Shelf Takedown”
shall mean an Underwritten Shelf Takedown or any proposed transfer or sale using a Registration Statement, including a Piggyback Registration.

 

“SPAC Holders”
shall have the meaning given in the Preamble.

 

“Subsequent Shelf
Registration” shall have the meaning given in Section 2.1.2.

 

“Transactions”
shall have the meaning given in the Recitals hereto.

 

“Transfer”
shall mean the (a) sale of, offer to sell, contract or agreement to sell, hypothecate, pledge, grant of any option to purchase or otherwise
dispose of or agreement to dispose of, directly or indirectly, or establishment or increase of a put equivalent position or liquidation
with respect to or decrease of a call equivalent position within the meaning of Section 16 of the Exchange Act with respect to, any security,
(b) entry into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership
of any security, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or (c) public announcement
of any intention to effect any transaction specified in clause (a) or (b).

 

“Underwriter”
shall mean a securities dealer who purchases any Registrable Securities as principal and not as part of such dealer’s market-making
activities.

 

“Underwritten
Offering” shall mean a Registration in which securities of the Company are sold to an Underwriter in a firm commitment underwriting
for distribution to the public.

 

“Underwritten
Shelf Takedown” shall have the meaning given in Section 2.1.4.

 

“Withdrawal Notice”
shall have the meaning given in Section 2.1.6.

 

    4

     

    

 

ARTICLE
II

REGISTRATIONS AND OFFERINGS

 

2.1   Shelf
Registration.

 

2.1.1   Filing.
The Company shall file within thirty (30) days after the Closing Date, and use commercially reasonable efforts to cause to be declared
effective as soon as practicable thereafter, a Registration Statement for a Shelf Registration on Form F-1 (the “Form F-1
Shelf”) or, if the Company is eligible to use a Registration Statement on Form F-3, a Shelf Registration on Form F-3 (the
“Form F-3 Shelf”), in each case, covering the resale of all the Registrable Securities (determined as of two
business days prior to such filing) on a delayed or continuous basis. Such Shelf shall provide for the resale of the Registrable Securities
included therein pursuant to any method or combination of methods legally available (the “Plan of Distribution”)
to, and requested by, any Holder named therein. The Company shall, upon request by any Holder named therein, use commercially reasonable
efforts to engage an underwriter or underwriters selected by the majority-in-interest of the Registrable Securities to participate in
the preparation of the Shelf to enable the Holders to resell Registrable Securities pursuant to the Plan of Distribution. The Company
shall maintain a Shelf in accordance with the terms hereof, and shall prepare and file with the SEC such amendments, including post-effective
amendments, and supplements as may be necessary to keep a Shelf continuously effective, available for use and in compliance with the provisions
of the Securities Act until such time as there are no longer any Registrable Securities. In the event the Company files a Form F-1 Shelf,
the Company shall use its commercially reasonable efforts to convert the Form F-1 Shelf (and any Subsequent Shelf Registration) to a Form
F-3 Shelf as soon as practicable after the Company is eligible to use Form F-3.

 

2.1.2   Subsequent
Shelf Registration. If any Shelf ceases to be effective under the Securities Act for any reason at any time while Registrable Securities
are still outstanding, the Company shall, subject to Section 3.4, use its commercially reasonable efforts to as promptly
as is reasonably practicable cause such Shelf to again become effective under the Securities Act (including obtaining the prompt withdrawal
of any order suspending the effectiveness of such Shelf), and shall use its commercially reasonable efforts to as promptly as is reasonably
practicable amend such Shelf in a manner reasonably expected to result in the withdrawal of any order suspending the effectiveness of
such Shelf or file an additional registration statement as a Shelf Registration (a “Subsequent Shelf Registration”)
registering the resale of all Registrable Securities (determined as of two business days prior to such filing), and pursuant to any Plan
of Distribution to, and requested by, any Holder named therein. The Company shall, upon request by any Holder named therein, use commercially
reasonable efforts to engage an underwriter or underwriters reasonably acceptable to the majority-in-interest of the Registrable Securities
to participate in the preparation of the Shelf to enable the Holders to resell Registrable Securities pursuant to the Plan of Distribution.
If a Subsequent Shelf Registration is filed, the Company shall use its commercially reasonable efforts to (i) cause such Subsequent Shelf
Registration to become effective under the Securities Act as promptly as is reasonably practicable after the filing thereof (it being
agreed that the Subsequent Shelf Registration shall be an automatic shelf registration statement (as defined in Rule 405 promulgated under
the Securities Act) if the Company is a well-known seasoned issuer (as defined in Rule 405 promulgated under the Securities Act) at the
most recent applicable eligibility determination date) and (ii) keep such Subsequent Shelf Registration continuously effective, available
for use and in compliance with the provisions of the Securities Act until such time as there are no longer any Registrable Securities.
Any such Subsequent Shelf Registration shall be on Form F-3 to the extent that the Company is eligible to use such form. Otherwise, such
Subsequent Shelf Registration shall be on another appropriate form.

 

2.1.3   Additional
Registrable Securities. In the event that any Holder holds Registrable Securities that are not registered for resale on a delayed
or continuous basis, the Company, upon request of a Biolog Equityholder (which for this purpose shall include affiliated entities) or
a SPAC Holder that holds at least five percent (5.0%) of the Registrable Securities, shall promptly use its commercially reasonable efforts
to cause the resale of such Registrable Securities to be covered by either, at the Company’s option, the Shelf (including by means
of a post-effective amendment) or a Subsequent Shelf Registration and cause the same to become effective as soon as practicable after
such filing and such Shelf or Subsequent Shelf Registration shall be subject to the terms hereof; provided, however, that
the Company shall only be required to cause such Registrable Securities to be so covered twice per calendar year for the Biolog Equityholders
and the SPAC Holders, respectively.

 

    5

     

    

 

2.1.4   Requests
for Underwritten Shelf Takedowns. At any time and from time to time when an effective Shelf is on file with the Commission, any Biolog
Equityholder or SPAC Holder (any of the Biolog Equityholders or the SPAC Holders being, in such case, a “Demanding Holder”)
may request to sell all or any portion of its Registrable Securities in an Underwritten Offering or other coordinated offering that is
registered pursuant to the Shelf (each, an “Underwritten Shelf Takedown”); provided that the Company
shall only be obligated to effect an Underwritten Shelf Takedown if such offering shall include Registrable Securities proposed to be
sold by the Demanding Holder with a total offering price reasonably expected to exceed, in the aggregate, $25 million or all of such Demanding
Holders remaining Registrable Securities (the “Minimum Takedown Threshold”). All requests for Underwritten Shelf
Takedowns shall be made by giving written notice to the Company, which shall specify the approximate number of Registrable Securities
proposed to be sold in the Underwritten Shelf Takedown. Subject to Section 2.4.4, the Demanding Holder shall have the right to
select the Underwriters for such offering (which shall consist of one or more reputable nationally recognized investment banks), subject
to the initial Company’s prior approval (which shall not be unreasonably withheld, conditioned or delayed). The Biolog Equityholders
may collectively demand not more than four (4) Underwritten Shelf Takedowns and SPAC Holders may collectively demand not more than two
(2) Underwritten Shelf Takedowns; provided, however, that the Biolog Equityholders and the SPAC Holders may not collectively
demand more than two (2) Underwritten Shelf Takedowns in any 12-month period. Notwithstanding anything to the contrary in this Agreement,
the Company may effect any Underwritten Offering pursuant to any then effective Registration Statement, including a Form F-3, that is
then available for such offering.

 

2.1.5   Reduction
of Underwritten Offering. If the managing Underwriter or Underwriters in an Underwritten Shelf Takedown, in good faith, advises the
Company, the Demanding Holders and the Holders requesting piggy-back rights pursuant to this Agreement with respect to such Underwritten
Shelf Takedown (the “Requesting Holders”) (if any) in writing that the dollar amount or number of Registrable
Securities that the Demanding Holders and the Requesting Holders (if any) desire to sell, taken together with all other Ordinary Shares
or other equity securities that the Company desires to sell and all Ordinary Shares or other equity securities, if any, that have been
requested to be sold in such Underwritten Offering pursuant to separate written contractual piggy-back registration rights held by any
other shareholders, exceeds the maximum dollar amount or maximum number of equity securities that can be sold in the Underwritten Offering
without adversely affecting the proposed offering price, the timing, the distribution method, or the probability of success of such offering
(such maximum dollar amount or maximum number of such securities, as applicable, the “Maximum Number of Securities”),
then the Company shall include in such Underwritten Offering, (1) first, the Registrable Securities of the Demanding Holders and the Requesting
Holders (if any) (in each case, pro rata based on the respective number of Registrable Securities that each Demanding Holder and
Requesting Holder (if any) has requested be included in such Underwritten Shelf Takedown and the aggregate number of Registrable Securities
that the Demanding Holders and Requesting Holders have requested be included in such Underwritten Shelf Takedown, provided that, if the
Registrable Securities held by the SPAC Holder accounts for twenty-five percent (25.0%) or less of the Registrable Securities requested
be included in such Underwritten Shelf Takedown, the total number of Registrable Securities of the SPAC Holder will be included towards
the Maximum Number of Securities) that can be sold without exceeding the Maximum Number of Securities; (ii) second, to the extent the
Maximum Number of Securities has not been reached under the foregoing clause (i), the Ordinary Shares or other equity securities that
the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities; and (iii) third, to the extent the
Maximum Number of Securities has not been reached under the foregoing clauses (i) and (ii), the Ordinary Shares or other equity securities
of other persons or entities that the Company is obligated to register in a Registration pursuant to separate contractual arrangements
with such persons and that can be sold without exceeding the Maximum Number of Securities. To facilitate the allocation of Registrable
Securities in accordance with the above provisions, the Company or the Underwriters may round the number of shares allocated to any Holder
to the nearest 100 shares. The Company shall not be required to include any Registrable Securities in such Underwritten Shelf Takedown
unless the Holders accept the terms of the underwriting as agreed upon between the Company and its Underwriters.

 

2.1.6   Withdrawal.
Prior to the filing of the applicable “red herring” prospectus or prospectus supplement used for marketing such Underwritten
Shelf Takedown, a majority-in-interest of the Demanding Holders initiating an Underwritten Shelf Takedown shall have the right to withdraw
from such Underwritten Shelf Takedown for any or no reason whatsoever upon written notification (a “Withdrawal Notice”)
to the Company and the Underwriter or Underwriters (if any) of their intention to withdraw from such Shelf Takedown; provided that
any Biolog Equityholder or SPAC Holder may elect to have the Company continue an Underwritten Shelf Takedown if the Minimum Takedown Threshold
would still be satisfied by the Registrable Securities proposed to be sold in the Underwritten Shelf Takedown by the Biolog Equityholders
or the SPAC Holders or any of their respective Permitted Transferees, as applicable. If withdrawn, a demand for an Underwritten Shelf
Takedown shall not constitute a demand for an Underwritten Shelf Takedown for purposes of Section 2.1.4; provided that,
if an Biolog Equityholder or a SPAC Holder elects to continue an Underwritten Shelf Takedown pursuant to the proviso in the immediately
preceding sentence, such Underwritten Shelf Takedown shall instead count as an Underwritten Shelf Takedown demanded by the Biolog Equityholders
or the SPAC Holders, as applicable, for purposes of Section 2.1.4. Following the receipt of any Withdrawal Notice, the Company
shall promptly forward such Withdrawal Notice to any other Holders that had elected to participate in such Shelf Takedown. Notwithstanding
anything to the contrary in this Agreement, the Company shall be responsible for the Registration Expenses incurred in connection with
a Shelf Takedown prior to its withdrawal under this Section 2.1.6.

 

    6

     

    

 

2.2   Piggyback
Registration.

 

2.2.1   Piggyback
Rights. Subject to Section 2.4.3, if the Company or any Holder proposes to conduct a registered offering of, or if the Company
proposes to file a Registration Statement under the Securities Act with respect to the Registration of, equity securities, or securities
or other obligations exercisable or exchangeable for, or convertible into equity securities, for its own account or for the account of
shareholders of the Company (or by the Company and by the shareholders of the Company including, without limitation, an Underwritten Shelf
Takedown pursuant to Section 2.1 hereof), other than a Registration Statement (or any registered offering with respect thereto)
(i) filed in connection with any employee stock option or other benefit plan, (ii) pursuant to a Registration Statement on Form F-4 (or
similar form that relates to a transaction subject to Rule 145 under the Securities Act or any successor rule thereto), (iii) for an offering
of debt that is convertible into equity securities of the Company or, (iv) for a dividend reinvestment plan or (v) for a rights offering,
then the Company shall give written notice of such proposed offering to all of the Holders of Registrable Securities as soon as practicable
but not less than ten (10) days before the anticipated filing date of such Registration Statement or, in the case of an Underwritten Offering
pursuant to a Shelf Registration, the applicable “red herring” prospectus or prospectus supplement used for marketing such
offering, which notice shall (A) describe the amount and type of securities to be included in such offering, the intended method(s) of
distribution, and the name of the proposed managing Underwriter or Underwriters, if any, in such offering, and (B) offer to all of the
Holders of Registrable Securities the opportunity to include in such registered offering such number of Registrable Securities as such
Holders may request in writing within five (5) days after receipt of such written notice (such registered offering, a “Piggyback
Registration”). Subject to Section 2.2.2, the Company shall, in good faith, cause such Registrable Securities to
be included in such Piggyback Registration and, if applicable, shall use its commercially reasonable efforts to cause the managing Underwriter
or Underwriters of such Piggyback Registration to permit the Registrable Securities requested by the Holders pursuant to this Section
2.2.1 to be included therein on the same terms and conditions as any similar securities of the Company included in such registered
offering and to permit the sale or other disposition of such Registrable Securities in accordance with the intended method(s) of distribution
thereof. The inclusion of any Holder’s Registrable Securities in a Piggyback Registration shall be subject to such Holder’s
agreement to enter into an underwriting agreement in customary form with the Underwriter(s) selected for such Underwritten Offering.

 

2.2.2   Reduction
of Piggyback Registration. If the managing Underwriter or Underwriters in an Underwritten Offering that is to be a Piggyback Registration,
in good faith, advises the Company and the Holders of Registrable Securities participating in the Piggyback Registration in writing that
the dollar amount or number of Ordinary Shares or other equity securities that the Company desires to sell, taken together with (i) the
Ordinary Shares or other equity securities, if any, as to which Registration or a registered offering has been demanded pursuant to separate
written contractual arrangements with persons or entities other than the Holders of Registrable Securities hereunder, (ii) the Registrable
Securities as to which registration has been requested pursuant to Section 2.2 hereof, and (iii) the Ordinary Shares or other equity
securities, if any, as to which Registration or a registered offering has been requested pursuant to separate written contractual piggy-back
registration rights of other shareholders of the Company, exceeds the Maximum Number of Securities, then:

 

(a)   If
the Registration or registered offering is undertaken for the Company’s account, the Company shall include in any such Registration
or registered offering (A) first, the Ordinary Shares or other equity securities that the Company desires to sell, which can be sold without
exceeding the Maximum Number of Securities; (B) second, to the extent that the Maximum Number of Securities has not been reached under
the foregoing clause (A), the Registrable Securities of Holders exercising their rights to register their Registrable Securities pursuant
to Section 2.2.1, pro rata, based on the respective number of Registrable Securities that each Holder has requested be included
in such Underwritten Offering and the aggregate number of Registrable Securities that the Holders have requested to be included in such
Underwritten Offering, which can be sold without exceeding the Maximum Number of Securities, provided that, if the Registrable Securities
held by the SPAC Holder accounts for twenty-five percent (25.0%) or less of the Registrable Securities requested be included in such Underwritten
Offering, the total number of Registrable Securities of the SPAC Holder will be included towards the Maximum Number of Securities; and
(C) third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (A) and (B), the Ordinary
Shares or other equity securities, if any, as to which Registration or a registered offering has been requested pursuant to written contractual
piggy-back registration rights of other shareholders of the Company, which can be sold without exceeding the Maximum Number of Securities;

 

    7

     

    

 

(b)   If
the Registration or registered offering is pursuant to a request by persons or entities other than the Holders of Registrable Securities,
then the Company shall include in any such Registration or registered offering (A) first, the Ordinary Shares or other equity securities,
if any, of such requesting persons or entities, other than the Holders of Registrable Securities, which can be sold without exceeding
the Maximum Number of Securities; (B) second, to the extent that the Maximum Number of Securities has not been reached under the foregoing
clause (A), the Registrable Securities of Holders exercising their rights to register their Registrable Securities pursuant to Section
2.2.1, pro rata, based on the respective number of Registrable Securities that each Holder has requested be included in such
Underwritten Offering and the aggregate number of Registrable Securities that the Holders have requested to be included in such Underwritten
Offering, which can be sold without exceeding the Maximum Number of Securities, provided that, if the Registrable Securities held by the
SPAC Holder accounts for twenty-five percent (25.0%) or less of the Registrable Securities requested be included in such Underwritten
Shelf Takedown, the total number of Registrable Securities of the SPAC Holder will be included towards the Maximum Number of Securities;
(C) third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (A) and (B), the Ordinary
Shares or other equity securities that the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities;
and (D) fourth, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (A), (B) and (C),
the Ordinary Shares or other equity securities for the account of other persons or entities that the Company is obligated to register
pursuant to separate written contractual arrangements with such persons or entities, which can be sold without exceeding the Maximum Number
of Securities; and

 

(c)   If
the Registration or registered offering is pursuant to a request by Holder(s) of Registrable Securities pursuant to Section 2.1
hereof, then the Company shall include in any such Registration or registered offering securities pursuant to Section 2.1.5.

 

2.2.3   Piggyback
Registration Withdrawal. Any Holder of Registrable Securities (other than a Demanding Holder, whose right to withdraw from an Underwritten
Shelf Takedown, and related obligations, shall be governed by Section 2.1.6) shall have the right to withdraw from a Piggyback
Registration for any or no reason whatsoever upon written notification to the Company and the Underwriter or Underwriters (if any) of
his, her or its intention to withdraw from such Piggyback Registration prior to the effectiveness of the Registration Statement filed
with the Commission with respect to such Piggyback Registration or, in the case of a Piggyback Registration pursuant to a Shelf Registration,
the filing of the applicable “red herring” prospectus or prospectus supplement with respect to such Piggyback Registration
used for marketing such transaction. The Company (whether on its own good faith determination or as the result of a request for withdrawal
by persons pursuant to separate written contractual obligations) may withdraw a Registration Statement filed with the Commission in connection
with a Piggyback Registration (which, in no circumstance, shall include the Shelf) at any time prior to the effectiveness of such Registration
Statement. Notwithstanding anything to the contrary in this Agreement (other than Section 2.1.6), the Company shall be responsible
for the Registration Expenses incurred in connection with the Piggyback Registration prior to its withdrawal under this Section 2.2.3.

 

2.2.4   Unlimited
Piggyback Registration Rights. For purposes of clarity, subject to Section 2.1.6, any Piggyback Registration effected pursuant
to Section 2.2 hereof shall not be counted as a demand for an Underwritten Shelf Takedown under Section 2.1.4 hereof.

 

2.3   Market
Stand-off. In connection with any Underwritten Offering of equity securities of the Company (other than a Block Trade), each Holder
given the opportunity to participate in the Underwritten Offering pursuant to the terms of this Agreement agrees that it shall not Transfer
any Ordinary Shares or other equity securities of the Company (other than those included in such offering pursuant to this Agreement),
without the prior written consent of the Company, during the 90-day period beginning on the date of pricing of such offering or such shorter
period during which the Company agrees not to conduct an underwritten primary offering of Ordinary Shares or other equity securities,
except in the event the Underwriters managing the offering otherwise agree by written consent; provided that (a) if any Holder elects
to participate in the Underwritten Offering and none of such Holder’s Registrable Securities are included in such Underwritten Offering,
then such Holder shall not be bound by this Section 2.3 with respect to such Underwritten Offering and (b) if the Underwriters
managing an Underwritten Offering consent to the early release of the Company’s lockup relating to such Underwritten Offering, the
terms of this Section 2.3 shall be deemed released with respect to such Underwritten Offering. Each such Holder agrees to execute
a customary lock-up agreement in favor of the Underwriters to such effect (in each case on substantially the same terms and conditions
as all such Holders).

 

    8

     

    

 

2.4   Block
Trades.

 

2.4.1   Notwithstanding
the foregoing, at any time and from time to time when an effective Shelf is on file with the Commission and effective, if a Demanding
Holder wishes to engage in an underwritten or other coordinated registered offering not involving a “roadshow,” an offer commonly
known as a “block trade” (a “Block Trade”), with a total offering price reasonably expected to exceed,
in the aggregate, either (x) $10 million or (y) all remaining Registrable Securities held by the Demanding Holder, then notwithstanding
the time periods provided for in Section 2.1.4, such Demanding Holder need only to notify the Company of the Block Trade at least
five (5) business days prior to the day such offering is to commence and the Company shall as expeditiously as possible use its commercially
reasonable efforts to facilitate such Block Trade; provided that the Demanding Holders representing a majority of the Registrable
Securities wishing to engage in the Block Trade shall use commercially reasonable efforts to work with the Company and any Underwriters
prior to making such request in order to facilitate preparation of the registration statement, prospectus and other offering documentation
related to the Block Trade.

 

2.4.2   Prior
to the filing of the applicable “red herring” prospectus or prospectus supplement used in connection with a Block Trade, a
majority-in-interest of the Demanding Holders initiating such Block Trade shall have the right to submit a Withdrawal Notice to the Company
and the Underwriter or Underwriters (if any) of their intention to withdraw from such Block Trade. Notwithstanding anything to the contrary
in this Agreement, the Company shall be responsible for the Registration Expenses incurred in connection with a block trade prior to its
withdrawal under this Section 2.4.2.

 

2.4.3   Notwithstanding
anything to the contrary in this Agreement, Section 2.2 hereof shall not apply to a Block Trade initiated by a Demanding Holder
pursuant to this Agreement.

 

2.4.4   The
Demanding Holder in a Block Trade shall have the right to select the Underwriters for such Block Trade (which shall consist of one or
more reputable nationally recognized investment banks).

 

ARTICLE
III

COMPANY PROCEDURES

 

3.1   General
Procedures. In connection with any Shelf and/or Shelf Takedown, the Company shall use its reasonable best efforts to effect such Registration
to permit the sale of such Registrable Securities in accordance with the intended Plan of Distribution thereof, and pursuant thereto the
Company shall, as soon as reasonably practicable:

 

3.1.1   prepare
and file with the Commission as soon as practicable a Registration Statement with respect to such Registrable Securities and use its reasonable
best efforts to cause such Registration Statement to become effective and remain effective until all Registrable Securities have ceased
to be Registrable Securities;

 

3.1.2   prepare
and file with the Commission such amendments and post-effective amendments to the Registration Statement, and such supplements to the
Prospectus, as may be reasonably requested by any Holder that holds at least five (5.0%) percent of the Registrable Securities registered
on such Registration Statement or any Underwriter of Registrable Securities or as may be required by the rules, regulations or instructions
applicable to the registration form used by the Company or by the Securities Act or rules and regulations thereunder to keep the Registration
Statement effective until all Registrable Securities covered by such Registration Statement are sold in accordance with the intended Plan
of Distribution set forth in such Registration Statement or supplement to the Prospectus;

 

    9

     

    

 

3.1.3   prior
to filing a Registration Statement or Prospectus, or any amendment or supplement thereto (except for supplements concerning Exchange Act
reports of the Company filed with respect to a Registration Statement or Prospectus for which forward incorporation by reference is unavailable),
furnish without charge to the Underwriters, if any, and the Holders of Registrable Securities included in such Registration, and such
Holders’ legal counsel, copies of such Registration Statement as proposed to be filed, each amendment and supplement to such Registration
Statement (in each case including all exhibits thereto and documents incorporated by reference therein), the Prospectus included in such
Registration Statement (including each preliminary Prospectus), and such other documents as the Underwriters and the Holders of Registrable
Securities included in such Registration or the legal counsel for any such Holders may request in order to facilitate the disposition
of the Registrable Securities owned by such Holders;

 

3.1.4   prior
to any public offering of Registrable Securities (i) register or qualify the Registrable Securities covered by the Registration Statement
under such securities or “blue sky” laws of such jurisdictions in the United States as the Holders of Registrable
Securities included in such Registration Statement (in light of their intended plan of distribution) may request (or provide evidence
satisfactory to such Holders that the Registrable Securities are exempt from such registration or qualification) and (ii) take such action
necessary to cause such Registrable Securities covered by the Registration Statement to be registered with or approved by such other governmental
authorities as may be necessary by virtue of the business and operations of the Company and do any and all other acts and things that
may be necessary or advisable to enable the Holders of Registrable Securities included in such Registration Statement to consummate the
disposition of such Registrable Securities in such jurisdictions; provided, however, that the Company shall not be required
to qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify or take any action to which
it would be subject to general service of process or taxation in any such jurisdiction where it is not then otherwise so subject;

 

3.1.5   cause
all such Registrable Securities to be listed on each national securities exchange on which similar securities issued by the Company are
then listed;

 

3.1.6   provide
a transfer agent and registrar for all such Registrable Securities no later than the effective date of such Registration Statement;

 

3.1.7   advise
each seller of such Registrable Securities, promptly after it shall receive notice or obtain knowledge thereof, of the issuance of any
stop order by the Commission suspending the effectiveness of such Registration Statement or the initiation or threatening of any proceeding
for such purpose and promptly use its reasonable best efforts to prevent the issuance of any stop order or to obtain its withdrawal if
such stop order should be issued;

 

3.1.8   at
least five (5) days prior to the filing of any Registration Statement or Prospectus or any amendment or supplement to such Registration
Statement or Prospectus (or such shorter period of time as may be necessary in order to comply with the Securities Act, the Exchange Act,
and the rules and regulations promulgated under the Securities Act or Exchange Act, as applicable), furnish a copy thereof to each seller
of such Registrable Securities or its counsel (excluding any exhibits thereto, any filing made under the Exchange Act that is to be incorporated
by reference therein and any supplement concerning Exchange Act reports of the Company filed with respect to a Registration Statement
or Prospectus for which forward incorporation by reference is unavailable);

 

3.1.9   notify
the Holders at any time when a Prospectus relating to such Registration Statement is required to be delivered under the Securities Act,
of the happening of any event as a result of which the Prospectus included in such Registration Statement, as then in effect, includes
a Misstatement, and then to correct such Misstatement as set forth in Section 3.4 hereof;

 

3.1.10   permit
a representative of any Holder, the Underwriters, if any, and any attorney or accountant retained by such Holder(s) or Underwriter to
participate, at each such person’s own expense, in the preparation of the Registration Statement, and cause the Company’s
officers, directors and employees to supply all information reasonably requested by any such representative, Underwriter, attorney or
accountant in connection with the Registration; provided, however, that such representatives or Underwriters agree to confidentiality
arrangements reasonably satisfactory to the Company, prior to the release or disclosure of any such information;

 

    10

     

    

 

3.1.11   obtain
a “comfort” letter from the Company’s independent registered public accountants in the event of an Underwritten Offering
or other coordinated offering that is registered pursuant to a Registration Statement, in customary form and covering such matters of
the type customarily covered by “comfort” letters as the managing Underwriter or other similar type of sales agent or placement
agent may reasonably request, and reasonably satisfactory to a majority-in-interest of the participating Holders;

 

3.1.12   on
the date the Registrable Securities are delivered for sale pursuant to such Registration, obtain an opinion, dated such date, of counsel
representing the Company for the purposes of such Registration, addressed to the Holders, the placement agent or sales agent, if any,
and the Underwriters, if any, covering such legal matters with respect to the Registration in respect of which such opinion is being given
as the Holders, placement agent, sales agent, or Underwriter may reasonably request and as are customarily included in such opinions and
negative assurance letters, and reasonably satisfactory to a majority-in-interest of the participating Holders;

 

3.1.13   in
the event of any Underwritten Offering or other coordinated offering that is registered pursuant to a Registration Statement, enter into
and perform its obligations under an underwriting agreement, sales agreement or placement agreement, in usual and customary form, with
the managing Underwriter, sales agent or placement agent of such offering;

 

3.1.14   make
available to its security holders, as soon as reasonably practicable, an earnings statement covering the period of at least twelve (12)
months beginning with the first day of the Company’s first full calendar quarter after the effective date of the Registration Statement
which satisfies the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder (or any successor rule then in effect),
provided that the Company will be deemed to have satisfied such requirement to the extent such information is filed on the Electronic
Data Gathering, Analysis and Retrieval system or any successor system (“EDGAR”);

 

3.1.15   if
the Registration involves the Registration of Registrable Securities involving gross proceeds in excess of $25 million with respect to
an Underwritten Offering pursuant to Section 2.1.4, use its reasonable efforts to make available senior executives of the Company
to participate in customary “road show” presentations that may be reasonably requested by the Underwriter in such Underwritten
Offering; and

 

3.1.16   otherwise,
in good faith, cooperate reasonably with, and take such customary actions as may reasonably be requested by the Holders, in connection
with such Registration.

 

Notwithstanding the foregoing,
the Company shall not be required to provide any documents or information to an Underwriter or other sales agent or placement agent if
such Underwriter or other sales agent or placement agent has not then been named with respect to the applicable Underwritten Offering
or other coordinated offering that is registered pursuant to a Registration Statement.

 

3.2   Registration
Expenses. The Registration Expenses of all Registrations shall be borne by the Company. It is acknowledged by the Holders that the
Holders shall bear all incremental selling expenses relating to the sale of Registrable Securities, such as Underwriters’ or agents’
commissions and discounts, brokerage fees, Underwriter marketing costs and, other than as set forth in the definition of “Registration
Expenses,” all reasonable fees and expenses of any legal counsel representing the Holders.

 

3.3   Stock
Distributions. In connection with any Shelf or Shelf Takedown, if the Company shall receive a request from a Holder of Registrable
Securities to effectuate a pro rata in-kind distribution for no consideration of such Registrable Securities pursuant to such Registration
to its members, partners, stockholders, as the case may be, then the Company shall deliver or cause to be delivered to the transfer agent
and registrar for the Registrable Securities an opinion of counsel to the Company reasonably acceptable to such transfer agent and registrar
that any legend referring to the Act may be removed upon such distribution of such Registrable Securities pursuant to such Registration,
provided that the distributee of such Registrable Securities is not and has not been for the preceding ninety (90) days an affiliate of
the Company (as defined in Rule 405 promulgated under the Act). The Company’s obligations hereunder are conditioned upon the receipt
of a representation letter reasonably acceptable to the Company from such Holder or the intended recipients of such Registrable Securities
regarding such proposed pro rata in-kind distribution for no consideration of such Registrable Securities.

 

    11

     

    

 

3.4   Requirements
for Participation in Registration Statement Underwritten Offerings. Notwithstanding anything in this Agreement to the contrary, if
any Holder does not provide the Company with its requested Holder Information, the Company may exclude such Holder’s Registrable
Securities from the applicable Registration Statement or Prospectus if the Company determines, based on the advice of counsel, that such
information is necessary to effect the registration and such Holder continues thereafter to withhold such information. No person may participate
in any Underwritten Offering or other coordinated offering for equity securities of the Company pursuant to a Registration initiated by
the Company hereunder unless such person (i) agrees to sell such person’s securities on the basis provided in any arrangements approved
by the Company and (ii) completes and executes all customary questionnaires, powers of attorney, indemnities, lock-up agreements, underwriting
or other agreements and other customary documents as may be reasonably required under the terms of such arrangements. The exclusion of
a Holder’s Registrable Securities as a result of this Section 3.4 shall not affect the registration of the other Registrable
Securities to be included in such Registration.

 

3.5   Suspension
of Sales; Adverse Disclosure; Restrictions on Registration Rights.

 

3.5.1   Upon
receipt of written notice from the Company that a Registration Statement or Prospectus contains a Misstatement, each of the Holders shall
forthwith discontinue disposition of Registrable Securities until it has received copies of a supplemented or amended Prospectus correcting
the Misstatement (it being understood that the Company hereby covenants to prepare and file such supplement or amendment as soon as practicable
after the time of such notice), or until it is advised in writing by the Company that the use of the Prospectus may be resumed.

 

3.5.2   If
the filing, initial effectiveness or continued use of a Registration Statement in respect of any Registration at any time would (a) require
the Company to make an Adverse Disclosure, (b) require the inclusion in such Registration Statement of financial statements that are unavailable
to the Company for reasons beyond the Company’s control, or (c) in the good faith judgment of the majority of the Board, cause serious
and irreparable harm to the Company and the majority of the Board concludes as a result that it is essential to defer such filing, initial
effectiveness or continued use at such time, the Company may, upon giving prompt written notice of such action to the Holders, delay the
filing or initial effectiveness of, or suspend use of, such Registration Statement for the shortest period of time determined in good
faith by the Company to be necessary for such purpose, but in any event no more than thirty (30) days. In the event the Company exercises
its rights under this Section 3.5.2, the Holders agree to suspend, immediately upon their receipt of the notice referred to above,
their use of the Prospectus relating to any Registration in connection with any sale or offer to sell Registrable Securities.

 

3.5.3   (a)
During the period starting with the date thirty (30) days prior to the Company’s good faith estimate of the date of the filing of,
and ending on a date ninety (90) days after the effective date of, a Company-initiated Registration and provided that the Company continues
to actively employ, in good faith, all reasonable efforts to maintain the effectiveness of the applicable Shelf Registration Statement,
or (b) if, pursuant to Section 2.1.4, Holders have requested an Underwritten Shelf Takedown and the Company and such Holders are
unable to obtain the commitment of underwriters to firmly underwrite such offering, the Company may, upon giving prompt written notice
of such action to the Holders, delay any other registered offering pursuant to Section 2.1.4 or 2.4.

 

3.5.4   The
right to delay or suspend any filing, initial effectiveness or continued use of a Registration Statement pursuant to Section 3.4.2
or a registered offering pursuant to Section 3.4.3 shall be exercised by the Company, in the aggregate, for not more than sixty
(60) consecutive calendar days or more than one hundred and twenty (120) total calendar days, in each case, during any twelve (12)-month
period.

 

3.6   Reporting
Obligations. As long as any Holder shall own Registrable Securities, the Company, at all times while it shall be a reporting company
under the Exchange Act, covenants to file timely (or obtain extensions in respect thereof and file within the applicable grace period)
all reports required to be filed by the Company after the date hereof pursuant to Sections 13(a) or 15(d) of the Exchange Act and to promptly
furnish the Holders with true and complete copies of all such filings; provided that any documents publicly filed or furnished
with the Commission pursuant to EDGAR shall be deemed to have been furnished or delivered to the Holders pursuant to this Section 3.6.
The Company further covenants that it shall take such further action as any Holder may reasonably request, all to the extent required
from time to time to enable such Holder to sell Registrable Securities held by such Holder without registration under the Securities Act
within the limitation of the exemptions provided by Rule 144 promulgated under the Securities Act (or any successor rule then in effect).
Upon the request of any Holder, the Company shall deliver to such Holder a written certification of a duly authorized officer as to whether
it has complied with such requirements.

 

    12

     

    

 

3.7   Acknowledgement.
Each Holder hereunder acknowledges its primary responsibilities under the Securities Act and accordingly will not sell or otherwise transfer
the Ordinary Shares or any interest therein without complying with the requirements of the Securities Act. Both the Company and its transfer
agent, and their respective directors, officers, employees and agents, may rely on this Section 3.7.

 

ARTICLE
IV

INDEMNIFICATION AND CONTRIBUTION

 

4.1   Indemnification.

 

4.1.1   The
Company agrees to indemnify and hold harmless, to the extent permitted by law, each Holder of Registrable Securities, its officers, directors
and agents and each person who controls such Holder (within the meaning of the Securities Act) against all losses, claims, damages, liabilities
and out-of-pocket expenses (including without limitation reasonable outside attorneys’ fees) as incurred arising out of or resulting
from any untrue or alleged untrue statement of material fact contained in any Registration Statement, Prospectus or preliminary Prospectus
or any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or
necessary to make the statements therein not misleading, except insofar as the same are caused by or contained in any information or affidavit
so furnished in writing to the Company by such Holder expressly for use therein, or any violation by the Company of the Securities Act
or any rule or regulation promulgated thereunder applicable to the Company and relating to action or inaction of the Company in connection
therewith.

 

4.1.2   In
connection with any Registration Statement in which a Holder of Registrable Securities is participating, such Holder shall furnish to
the Company in writing such information and affidavits with respect to such Holder as the Company reasonably requests for use in connection
with any such Registration Statement or Prospectus (the “Holder Information”) and, to the extent permitted by
law, shall indemnify and hold harmless the Company, its directors, officers and agents and each person who controls the Company (within
the meaning of the Securities Act) against all losses, claims, damages, liabilities and out-of-pocket expenses (including without limitation
reasonable outside attorneys’ fees) as incurred arising out of or resulting from any untrue or alleged untrue statement of material
fact contained in any Registration Statement, Prospectus or preliminary Prospectus or any amendment thereof or supplement thereto or any
omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading,
but only to the extent that such untrue or alleged untrue statement or omission or alleged omission is contained in any information or
affidavit so furnished in writing by such Holder expressly for use therein; provided, however, that the obligation to indemnify
shall be several, not joint and several, among such Holders of Registrable Securities, and the liability of each such Holder of Registrable
Securities shall be in proportion to and limited to the net proceeds received by such Holder from the sale of Registrable Securities pursuant
to such Registration Statement. The Holders of Registrable Securities shall indemnify the Underwriters, their officers, directors and
each person who controls such Underwriters (within the meaning of the Securities Act) to the same extent as provided in the foregoing
with respect to indemnification of the Company.

 

4.1.3   Any
person entitled to indemnification herein shall (i) give prompt written notice to the indemnifying party of any claim with respect to
which it seeks indemnification (provided that the failure to give prompt notice shall not impair any person’s right to indemnification
hereunder to the extent such failure has not materially prejudiced the indemnifying party) and (ii) unless in such indemnified party’s
reasonable judgment a conflict of interest between such indemnified and indemnifying parties may exist with respect to such claim, permit
such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party. If such defense
is assumed, the indemnifying party shall not be subject to any liability for any settlement made by the indemnified party without its
consent (but such consent shall not be unreasonably withheld). An indemnifying party who is not entitled to, or elects not to, assume
the defense of a claim shall not be obligated to pay the fees and expenses of more than one counsel for all parties indemnified by such
indemnifying party with respect to such claim, unless in the reasonable judgment of any indemnified party a conflict of interest may exist
between such indemnified party and any other of such indemnified parties with respect to such claim. No indemnifying party shall, without
the consent of the indemnified party, consent to the entry of any judgment or enter into any settlement which cannot be settled in all
respects by the payment of money (and such money is so paid by the indemnifying party pursuant to the terms of such settlement) or which
settlement does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release
from all liability in respect to such claim or litigation.

 

    13

     

    

 

4.1.4   The
indemnification provided for under this Agreement shall remain in full force and effect regardless of any investigation made by or on
behalf of the indemnified party or any officer, director or controlling person of such indemnified party and shall survive the transfer
of securities. The Company and each Holder of Registrable Securities participating in an offering also agrees to make such provisions
as are reasonably requested by any indemnified party for contribution to such party in the event the Company’s or such Holder’s
indemnification is unavailable for any reason.

 

4.1.5   If
the indemnification provided under Section 4.1 hereof from the indemnifying party is unavailable or insufficient to hold harmless
an indemnified party in respect of any losses, claims, damages, liabilities and out-of-pocket expenses referred to herein, then the indemnifying
party, in lieu of indemnifying the indemnified party, shall contribute to the amount paid or payable by the indemnified party as a result
of such losses, claims, damages, liabilities and out-of-pocket expenses in such proportion as is appropriate to reflect the relative fault
of the indemnifying party and the indemnified party, as well as any other relevant equitable considerations. The relative fault of the
indemnifying party and indemnified party shall be determined by reference to, among other things, whether any action in question, including
any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact, was made by, or relates
to information supplied by, such indemnifying party or indemnified party, and the indemnifying party’s and indemnified party’s
relative intent, knowledge, access to information and opportunity to correct or prevent such action; provided, however,
that the liability of any Holder under this Section 4.1.5 shall be limited to the amount of the net proceeds received by such Holder
in such offering giving rise to such liability. The amount paid or payable by a party as a result of the losses or other liabilities referred
to above shall be deemed to include, subject to the limitations set forth in Sections 4.1.1, 4.1.2 and 4.1.3 above,
any legal or other fees, charges or out-of-pocket expenses reasonably incurred by such party in connection with any investigation or proceeding.
The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 4.1.5 were determined
by pro rata allocation or by any other method of allocation, which does not take account of the equitable considerations referred
to in this Section 4.1.5. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
Act) shall be entitled to contribution pursuant to this Section 4.1.5 from any person who was not guilty of such fraudulent misrepresentation.

 

ARTICLE
V

MISCELLANEOUS

 

5.1   Notices.
All notices, requests, claims, demands and other communications among the parties shall be in writing and shall be deemed to have been
duly given (i) when delivered in person, (ii) when delivered after posting in the United States mail having been sent registered or certified
mail return receipt requested, postage prepaid, (iii) when delivered by FedEx or other nationally recognized overnight delivery service
or (iv) when e-mailed during normal business hours (and otherwise as of the immediately following business day), addressed as follows:

 

If to the Company, to:

 

Biolog-id SA

46, rue du Général Leclerc

92100 Boulogne-Billancourt

France

Attention:

Email:

 

with copies (which shall not constitute notice) to:

 

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C.

One Financial Center

Boston, MA 02111

Attention:

E-mail:

 

If to any Holder, to such address indicated on
the Company’s records with respect to such Holder or to such other address or addresses as such Holder may from time to time designate
in writing.

 

    14

     

    

 

5.2   Assignment;
No Third Party Beneficiaries.

 

5.2.1   This
Agreement and the rights, duties and obligations of the Company hereunder may not be assigned or delegated by the Company in whole or
in part.

 

5.2.2   A
Holder may assign or delegate such Holder’s rights, duties or obligations under this Agreement, in whole or in part, to any person
to whom it transfers Registrable Securities; provided that such Registrable Securities remain Registrable Securities following such transfer
and such person agrees to become bound by the terms and provisions of this Agreement.

 

5.2.3   No
assignment by any party hereto of such party’s rights, duties and obligations hereunder shall be binding upon or obligate the Company
unless and until the Company shall have received (i) written notice of such assignment as provided in Section 5.1 hereof and (ii)
the written agreement of the assignee, in a form reasonably satisfactory to the Company, to be bound by the terms and provisions of this
Agreement (which may be accomplished by an addendum or certificate of joinder to this Agreement).

 

5.2.4   Subject
to the foregoing, this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective permitted successors
and assigns. Any attempted assignment in violation of the terms of this Section 5.2 shall be null and void, ab initio.

 

5.2.5   This
Agreement shall not confer any rights or benefits on any persons that are not parties hereto, other than as expressly set forth in this
Agreement and Section 5.2 hereof.

 

5.3   Severability.
This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the
validity or enforceability of this Agreement or of any other term or provision thereof. Furthermore, in lieu of any such invalid or unenforceable
term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to
such invalid or unenforceable provision as may be possible that is valid and enforceable.

 

5.4   Captions;
Counterparts. The headings, subheadings and captions contained in this Agreement are inserted for convenience only and shall not affect
in any way the meaning or interpretation of this Agreement. This Agreement and any amendment hereto may be executed in one or more counterparts,
each of which shall be deemed to be an original, but all of which shall constitute one and the same agreement. Delivery of an executed
counterpart of a signature page to this Agreement or any amendment hereto by electronic means, including docusign, e-mail, or scanned
pages shall be effective as delivery of a manually executed counterpart to this Agreement or any amendment hereto.

 

5.5   Governing
Law. This Agreement, and all claims or causes of action based upon, arising out of, or related to this Agreement, shall be governed
by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision
or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the law of any jurisdiction other
than the State of Delaware.

 

    15

     

    

 

5.6   Jurisdiction;
Waiver of Jury Trial.

 

5.6.1   Each
of the parties hereto irrevocably and unconditionally submits to the exclusive jurisdiction of the Chancery Court of the State of Delaware
(or, if the Chancery Court of the State of Delaware declines to accept jurisdiction, any state or federal court sitting in the Borough
of Manhattan, State of New York, New York County), for the purposes of any Proceeding (as defined in the Business Combination Agreement),
claim, demand, action or cause of action (a) arising under this Agreement or (b) in any way connected with or related or incidental to
the dealings of the parties hereto in respect of this Agreement, and irrevocably and unconditionally waives any objection to the laying
of venue of any such Proceeding in any such court, and further irrevocably and unconditionally waives and agrees not to plead or claim
in any such court that any such Proceeding has been brought in an inconvenient forum. Each party hereby irrevocably and unconditionally
waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any Proceeding, claim, demand, action
or cause of action against such party (i) arising under this Agreement or (ii) in any way connected with or related or incidental to the
dealings of the parties hereto in respect of this Agreement, (A) any claim that such party is not personally subject to the jurisdiction
of the courts as described in this Section 5.5 for any reason, (B) that such party or such party’s property is exempt or
immune from the jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice,
attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (C) that (x) the Proceeding,
claim, demand, action or cause of action in any such court is brought against such party in an inconvenient forum, (y) the venue of such
Proceeding, claim, demand, action or cause of action against such party is improper or (z) this Agreement, or the subject matter hereof,
may not be enforced against such party in or by such courts. Each party agrees that service of any process, summons, notice or document
by registered mail to such party’s respective address set forth in Section 5.5 shall be effective service of process for
any such Proceeding, claim, demand, action or cause of action.

 

5.6.2   THE
PARTIES HERETO EACH HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY PROCEEDING, CLAIM, DEMAND,
ACTION, OR CAUSE OF ACTION (I) ARISING UNDER THIS AGREEMENT OR UNDER ANY ANCILLARY DOCUMENT OR (II) IN ANY WAY CONNECTED WITH OR RELATED
OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AGREEMENT, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER
IN CONTRACT, TORT, EQUITY, OR OTHERWISE. THE PARTIES HERETO EACH HEREBY AGREES AND CONSENTS THAT ANY SUCH PROCEEDING, CLAIM, DEMAND, ACTION
OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES HERETO MAY FILE AN ORIGINAL COUNTERPART OF A COPY
OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.
EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE,
THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B) EACH SUCH PARTY UNDERSTANDS AND
HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) EACH SUCH PARTY MAKES THIS WAIVER VOLUNTARILY AND (D) EACH SUCH PARTY HAS BEEN INDUCED
TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 5.5.

 

5.7   Amendments
and Modifications. Upon the written consent of (a) the Company and (b) the Holders of a majority of the total Registrable Securities
as of the time of any waiver or amendment, compliance with any of the provisions, covenants and conditions set forth in this Agreement
may be waived, or any of such provisions, covenants or conditions may be amended or modified; provided, however, that in
the event any such waiver, amendment or modification would be adverse in any material respect to the material rights or obligations hereunder
of a Holder of the Registrable Securities, the written consent of such Holder will also be required; provided further that in the
event any such waiver, amendment or modification would be disproportionate and adverse in any material respect to the material rights
or obligations hereunder of a Holder, the written consent of such Holder will also be required. No course of dealing between any Holder
or the Company and any other party hereto or any failure or delay on the part of a Holder or the Company in exercising any rights or remedies
under this Agreement shall operate as a waiver of any rights or remedies of any Holder or the Company. No single or partial exercise of
any rights or remedies under this Agreement by a party shall operate as a waiver or preclude the exercise of any other rights or remedies
hereunder or thereunder by such party. Any waiver, amendment or modification effected in accordance with this Section 5.6 shall be binding
on all parties hereto, regardless of whether any such party consented thereto.

 

    16

     

    

 

5.8   Termination
of Existing Registration Rights. The registration rights granted under this Agreement shall supersede any registration, qualification
or similar rights of the Holders with respect to any shares or securities of SPAC or the Company granted under any other agreement, including,
but not limited to, that certain Registration and Shareholder Rights Agreement dated as of December 8, 2022, among SPAC and the other
parties thereto, and any of such preexisting registration, qualification or similar rights and such agreements shall be terminated and
of no further force and effect effective as of immediately prior to the effective time of the Merger.

 

5.9   Entire
Agreement. This Agreement (including all agreements entered into pursuant hereto and all certificates and instruments delivered pursuant
hereto and thereto) constitute the entire agreement of the parties with respect to the subject matter hereof and supersede all prior and
contemporaneous agreements, representations, understandings, negotiations and discussions between the parties, whether oral or written.

 

5.10   Term.
This Agreement shall terminate with respect to any Holder on the date that such Holder no longer holds any Registrable Securities. The
provisions of Sections 3.5, 5.1, 5.4, and 5.5, and Article IV shall survive any termination.

 

5.11   Holder
Information. Each Holder agrees, if requested in writing, to represent to the Company the total number of Registrable Securities held
by such Holder in order for the Company to make determinations hereunder.

 

[SIGNATURE PAGES FOLLOW]

 

    17

     

    

 

IN WITNESS WHEREOF, the undersigned
have caused this Agreement to be executed as of the date first written above.

 

	 	COMPANY:
	 	 
	 	BIOLOG-ID S.A.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

[Signature Page to Registration Rights Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, the undersigned
have caused this Agreement to be executed as of the date first written above.

 

	 	GENESIS GROWTH TECH LLC
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

[Signature Page to Registration Rights Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, the undersigned
have caused this Agreement to be executed as of the date first written above.

 

	 	[________________]	 

 

	 	By:	 
	 	 	Name:
	 	 	Title:

 

[Signature Page to Registration Rights Agreement]

 

     

     

    

 

Schedule A

 

SPAC Holders

 

Genesis Growth Tech LLC

 

    Schedule A

     

    

 

Schedule B

 

Biolog Equityholders

 

Monsieur Jean-Claude Mongrenier

MGR Conseils SARL

La Financière Xerys SCA

La Financière Xerys-2 SCA

La Financière Xerys-3 SCA

La Financière Xerys-4 SCA

La Financière Xerys-5 SCA

La Financière Xerys-6 SCA

La Financière Xerys-8 SCA

La Financière Xerys-9 SCA

La Financière Xerys-13 SCA

Xerys Venture Capital

Xerys Venture Capital 2

Xerys Innovation 1

Xerys Capital Luxembourg

Electro Caloriques SAS

Ijinus SAS

Monsieur François Luc Monge

Monsieur Antoine Bachoud

Monsieur Yann Campion

Xerys Entreprises

Xerys Developpement SCSP RAIF

Xerys PEA

Xerys Capital France Health

Xerys Capital France Growth

Xerys Capital France Biolog

Xerys Capital France Life

Xerys Capital France Premium

Private Equity RB

Biolog Capdev

Horizon Capdev

Xerys Croissance

La Financière Xerys-21

La Financière Xerys-25

 

 

Schedule BExhibit 10.5

 

CONFIDENTIALITY AND LOCKUP AGREEMENT 

 

This Confidentiality and Lockup Agreement is dated
as of [●], 2022 and is between Biolog-id, a French société anonyme registered with the French Registry of commerce
and companies under number 481 216 430 R.C.S. Nanterre (the “Company”), and each of the shareholder parties
identified on Exhibit A hereto and the other persons who enter into a joinder to this Agreement substantially in the form of Exhibit
B hereto with the Company in order to become a “Shareholder Party” for purposes of this Agreement (collectively, the “Shareholder
Parties”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Business Combination
Agreement (as defined below).

 

BACKGROUND: 

 

WHEREAS, the Shareholder Parties own or
will own equity interests in Genesis Growth Tech Acquisition Corp., a Cayman Islands exempted company (“SPAC”),
and/or the Company;

 

WHEREAS, pursuant to that certain Business
Combination Agreement, dated as of [●], 2022 (as it may be amended, supplemented, restated or otherwise modified from time to time,
the “Business Combination Agreement”), by and between the Company and SPAC, the SPAC will merge with an into
the Company with the Company continuing as the surviving entity (the “Merger”); and

 

WHEREAS, in connection with the Merger
and effective upon the consummation thereof, the parties hereto wish to set forth herein certain understandings between such parties with
respect to confidentiality and restrictions on transfer of equity interests in the Company.

 

NOW, THEREFORE, the parties agree as follows:

 

ARTICLE I 

INTRODUCTORY MATTERS 

 

1.1 Defined Terms. In addition to
the terms defined elsewhere herein, the following terms have the following meanings when used herein with initial capital letters:

 

“Agreement” means this
Confidentiality and Lockup Agreement, as the same may be amended, supplemented, restated or otherwise modified from time to time in accordance
with the terms hereof.

 

“Company” has the meaning
set forth in the Preamble.

 

“Confidential Information”
means any information concerning the Company or its Subsidiaries that is furnished after the date of this Agreement by or on behalf of
the Company or its designated representatives to a Shareholder Party or its designated representatives, together with any notes, analyses,
reports, models, compilations, studies, documents, records or extracts thereof containing, based upon or derived from such information,
in whole or in part; provided, however, that Confidential Information does not include information:

 

(i) that is generally known to the public at the
time of disclosure or becomes generally known without violation of this Agreement by the receiving Shareholder Party or its designated
representatives;

 

(ii) that is in the Shareholder Party’s
possession or the possession of the Shareholder Party’s representatives at the time of disclosure otherwise than as a result of
Shareholder Party’s or its designated representatives’ breach of any legal or fiduciary obligation of confidentiality owed
to the Company or its affiliates;

 

    

     

    

 

(iii) that becomes known to the receiving Shareholder
Party or its designated representatives through disclosure by sources, other than the Company, provided that such sources are not known
by the receiving Shareholder Party to be bound by a confidentiality agreement with, or other contractual, legal, or fiduciary obligation
of confidentiality to, the Company or its affiliates with respect to such information;

 

(iv) that is independently developed by the receiving
Shareholder Party or its designated representatives without use of or reference to the Confidential Information; or

 

(v) that the receiving Shareholder Party or its
designated representatives is required, in the good faith determination of such receiving Shareholder Party or designated representative,
to disclose by applicable Law, regulation or legal process, provided that such receiving Shareholder Party or designated representative
takes reasonable steps to minimize the extent of any such required disclosure, discloses only that portion of the Confidential Information
that such Shareholder Party’s legal counsel advises is legally required to be disclosed, and, if permissible, provides the Company
with the opportunity to seek a protective order or other appropriate remedy to prevent such disclosure, provided further that no such
steps to minimize disclosure shall be required where disclosure is made in connection with a routine audit or examination by a bank examiner
or auditor and such audit or examination does not specifically reference the Company or this Agreement.

 

“covered shares” has
the meaning set forth in Section 3.1.

 

“designated representatives”
means, with respect to a Shareholder Party, (a) its and its Affiliates’ directors, managers, officers, attorneys, accountants, consultants,
insurers, financing sources and other advisors in connection with such Shareholder Party’s investment in the Company and (b) any
of such Shareholder Party’s or their respective Affiliates’ partners, members, shareholders, directors, managers, officers,
other fiduciaries, employees or agents in the ordinary course of business, so long as such Person has agreed to maintain the confidentiality
of the information relating to the Company provided to it.

 

“Exchange Act” means
the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, as the same may be amended from
time to time.

 

“immediate family” has
the meaning set forth in Section 3.1(b).

 

“Letter Agreement” means
the Letter Agreement, dated December 8, 2021, by and among SPAC, the Sponsor and the other signatories thereto.

 

“Lock-Up Period” has
the meaning set forth in Section 3.1(a).

 

“Non-Recourse Party”
means any past, present or future director, officer, employee, incorporator, member, partner, shareholder, Affiliate, agent, attorney,
advisor or representative or Affiliate of any named party to this Agreement and any past, present or future director, officer, employee,
incorporator, member, partner, shareholder, Affiliate, agent, attorney, advisor or representative or Affiliate of any of the foregoing.

 

“Permitted Transferees”
means with respect to a Shareholder Party, a transferee of shares that agrees to become party to, and to be bound to the same extent as
its Transferor by the terms of, this Agreement.

 

“shares” means Company
Ordinary Shares, or American Depositary Shares representing Company Ordinary Shares, received by the Sponsor or Nomura Securities International,
Inc. or any of their respective Permitted Transferees pursuant to the Business Combination Agreement and the Company Ordinary Shares,
or American Depositary Shares representing Company Ordinary Shares, held or received by the other Shareholder Parties immediately following
the Merger.

 

    2

     

    

 

“Sponsor” means Genesis
Growth Tech LLC, a Cayman Islands limited liability company.

 

“Shareholder Parties”
has the meaning set forth in the Preamble.

 

1.2 Construction. The language used
in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rule of strict construction
will be applied against any party. Unless the context otherwise requires: (a) “or” is disjunctive but not exclusive, (b) words
in the singular include the plural, and in the plural include the singular, and (c) the words “hereof”, “herein”,
and “hereunder” and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any
particular provision of this Agreement, and Section references are to sections of this Agreement unless otherwise specified.

 

ARTICLE II 

CONFIDENTIALITY 

 

2.1 Confidentiality. Each Shareholder
Party agrees that it will, and will direct its designated representatives to, keep confidential and not disclose any Confidential Information;
provided, however, that the Shareholder Parties may disclose Confidential Information (a) to their respective designated
representatives and (b) as the Company may otherwise consent in writing; provided, further, however, that each Shareholder
Party agrees to be responsible for any breaches of this Article II by such Shareholder Party’s designated representatives
and agrees, at its sole expense, to take commercially reasonable measures (including, but not limited to, court proceedings) to restrain
its designated representatives from prohibited or unauthorized disclosure of the Confidential Information.

 

ARTICLE III 

LOCKUP 

 

3.1 Lockup. (a) During the period
beginning at the Closing and continuing to and including the date that is 180 days after the Closing Date (the “Lock-Up Period”),
each such Shareholder Party agrees not to, directly or indirectly, offer, sell, contract to sell, pledge, grant any option to purchase,
make any short sale or otherwise dispose of any shares, or any options or warrants to purchase any shares, or any securities convertible
into, exchangeable for or that represent the right to receive shares, or any interest in any of the foregoing, whether now owned or hereinafter
acquired, owned directly by the undersigned (including holding as a custodian) or with respect to which the undersigned has beneficial
ownership within the rules and regulations of the U.S. Securities and Exchange Commission (collectively, the “covered shares”).
The foregoing restriction is expressly agreed to preclude such Shareholder Parties from engaging in any hedging or other transaction which
is designed to or which reasonably could be expected to lead to or result in a sale or disposition of the covered shares even if such
covered shares would be disposed of by someone other than such Shareholder Parties. Such prohibited hedging or other transactions would
include, without limitation, any short sale or any purchase, sale or grant of any right (including, without limitation, any put or call
option) with respect to any of the covered shares or with respect to any security that includes, relates to, or derives any significant
part of its value from such covered shares.

 

    3

     

    

 

(b) Notwithstanding the foregoing, a Shareholder
Party may transfer or dispose of its shares following the Closing (i) by will or intestacy, (ii) as a bona fide gift or gifts, including
to charitable organizations, (iii) to any trust, partnership, limited liability company or other entity for the direct or indirect benefit
of the undersigned or the immediate family of the undersigned (for purposes of this Section 3.1, “immediate family”
shall mean any relationship by blood, current or former marriage or adoption, not more remote than first cousin), (iv) to any immediate
family member or other dependent, (v) as a distribution or dividend to limited partners, members or shareholders of such Shareholder Party,
(vi) to its Affiliated investment fund, other Affiliated entity controlled by, any account managed by, or designee of, such Shareholder
Party or its or their Affiliates, (vii) to a nominee or custodian of a Person to whom a disposition or transfer would be permissible under
clauses (i) through (vi) above, (viii) pursuant to an order or decree of a Governmental Entity, (ix) to the Company or its Subsidiary
or parent entities upon death, disability or termination of employment, in each case, of such holder, (x) pursuant to a bona fide tender
offer, merger, consolidation or other similar transaction in each case made to all holders of the shares involving a Change of Control
(as defined below) (including negotiating and entering into an agreement providing for any such transaction), provided that in the event
that such tender offer, merger, consolidation or other such transaction is not completed, such Shareholder Party’s shares shall
remain subject to the provisions of this Section 3.1, (xi) to the Company (1) pursuant to the exercise, in each case on a “cashless”
or “net exercise” basis, of any option to purchase shares granted by the Company pursuant to any employee benefit plans or
arrangements which are set to expire during the Lock-Up Period, where any shares received by the undersigned upon any such exercise will
be subject to the terms of this Section 3.1, or (2) for the purpose of satisfying any withholding taxes (including estimated taxes)
due as a result of the exercise of any option to purchase shares or the vesting of any restricted stock awards granted by the Company
pursuant to employee benefit plans or arrangements where any shares received by such Shareholder Party upon any such exercise or vesting
will be subject to the terms of this Section 3.1, or (xii) in any transaction relating to Company Ordinary Shares acquired by the
Shareholder Party in open market transactions; or (xiii) with the prior written consent of the Company; provided that:

 

(1) in the case of each transfer or distribution
pursuant to clauses (ii) through (vii) above, (a) each donee, trustee, distributee or transferee, as the case may be, agrees to be bound
in writing by the restrictions set forth in this Section 3.1; and (b) any such transfer or distribution shall not involve
a disposition for value, other than with respect to any such transfer or distribution for which the transferor or distributor receives
(x) equity interests of such transferee or (y) such transferee’s interests in the transferor;

 

(2) in the case of each transfer or distribution
pursuant to clauses (ii) through (vii) above, if any public reports or filings (including filings under Section 16(a) of the Exchange
Act) reporting a reduction in beneficial ownership of shares shall be required or shall be voluntarily made during the Lock-Up Period
(x) such Shareholder Party shall provide the Company prior written notice informing them of such report or filing and (y) such report
or filing shall disclose that such donee, trustee, distributee or transferee, as the case may be, agrees to be bound in writing by the
restrictions set forth herein; and

 

(3) for purposes of clause (x) above, “Change
of Control” shall mean the transfer to or acquisition by (whether by tender offer, merger, consolidation, division or other
similar transaction), in one transaction or a series of related transactions, a Person or group of Affiliated Persons (other than an underwriter
pursuant to an offering), of the Company’s voting securities if, after such transfer or acquisition, such Person or group of Affiliated
Persons would beneficially own more than 50% of the outstanding voting securities of the Company (or the surviving entity).

 

(c) Each Shareholder Party shall be permitted
to enter into a trading plan established in accordance with Rule 10b5-1 under the Exchange Act during the applicable Lock-Up Period so
long as no transfers or other dispositions of such Shareholder Party’s shares in contravention of Section 3.1 are effected
prior to the expiration of the Lock-Up Period.

 

(d) Each Shareholder Party also agrees and consents
to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the covered shares
except in compliance with the foregoing restrictions and to the addition of a legend to such Shareholder Party’s shares describing
the foregoing restrictions.

 

    4

     

    

 

(e) If the Company enters into a lockup agreement
or similar arrangement (or any amendment thereof or waiver thereof, except as set forth in Section 4.3(b) with respect to lock-up
releases) in respect of the Merger with any other person, including any other Company shareholder, that contains any provision that is
more favorable to such other person than the provisions of this Agreement (a “More Favorable Agreement”), the
Company shall promptly provide the Shareholder Parties with notice thereof and a copy of such provision, and upon such notice, this Agreement
shall be deemed to be amended to conform the provisions of this Agreement with such More Favorable Agreement.

 

3.2 Termination of Founder Shares Lockup.
Subject to, and conditioned upon the occurrence and effective as of, the Closing, Section 5 of the Letter Agreement shall be amended and
restated in its entirety as follows:

 

“5.Reserved.”

 

ARTICLE IV 

GENERAL PROVISIONS 

 

4.1 Termination. Subject to Section
4.13 or the early termination of any provision as a result of an amendment to this Agreement agreed to by the Company Board and the
Shareholder Parties, as provided under Section 4.3, this Agreement shall not terminate with respect to a Shareholder Party or its
Permitted Transferees until the expiration of the Lock-Up Period.

 

4.2 Notices. All notices, requests,
claims, demands and other communications among the parties shall be in writing and shall be deemed to have been duly given (i) when delivered
in person, (ii) when delivered after posting in the United States mail having been sent registered or certified mail return receipt requested,
postage prepaid, (iii) when delivered by FedEx or other nationally recognized overnight delivery service or (iv) when e-mailed during
normal business hours (and otherwise as of the immediately following Business Day), addressed as follows:

 

	 	If to the Company, to:
	 	 	 
	 	Biolog-id
	 	46/48 Avenue du Général Leclerc
	 	92100 Boulogne-Billancourt
	 	Attention:	Troy Hilsenroth; Arnaud Saint-Michel; Jean Claude Mongrenier
	 	Email:	troyh@biologllc.com; arnaud.saintmichel@biolog-id.com; jean claude.mongrenier@biolog-id.com
	 	 	 
	 	with copies (which shall not constitute notice) to:
	 	 	 
	 	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	 	One Financial Center
	 	Boston, MA 02111
	 	Attention:	Stephen Osborn, Esq.
	 	E-mail:	SMOsborn@mintz.com

  

    5

     

    

 

	 	and	 
	 	 	 
	 	Charles Russell Speechlys
	 	41 Avenue de Friedland
	 	75008 Paris
	 	France
	 	Attention:	Renaud Ferry
	 	Email:	renaud.ferry@crsblaw.com

 

	 	If to SPAC, to:
	 	 
	 	c/o Genesis Growth Tech Acquisition Corp.
	 	Bahnhofstrasse 3
	 	Hergiswil Nidwalden, Switzerland 6052
	 	Attention:	Eyal Perez
	 	Email:	ep@genfunds.com
	 	 
	 	with a copy (which shall not constitute notice) to :
	 	 
	 	O’Melveny & Myers LLP
	 	Two Embarcadero Center, 28th Floor
	 	San Francisco, CA 94111
	 	Attention:	Noah Kornblith, Esq.
	 	Email:	nkornblith@omm.com

 

If to any Shareholder Party, to such address indicated
on the Company’s records with respect to such Shareholder Party or to such other address or addresses as such Shareholder Party
may from time to time designate in writing.

 

4.3 Amendment; Waiver; Pro Rata Release.
(a) The terms and provisions of this Agreement may be amended or modified in whole or in part only by a duly authorized agreement in writing
executed by the Company and Shareholder Parties holding a majority of the shares then held by the Shareholder Parties in the aggregate
as to which this Agreement has not been terminated pursuant to Section 4.1.

 

(b) In the event that a release is granted to
any Shareholder Party relating to the lock-up restrictions set forth in Article III above, the same percentage of the undersigned’s
Company Ordinary Shares (the “Pro-Rata Release”) shall be immediately and fully released on the same terms from any
remaining lock-up restrictions set forth herein; provided that no Pro-Rata Release shall be required for any release approved by
the Board of Directors of the Company.

 

(c) Except as expressly set forth in this Agreement,
neither the failure nor delay on the part of any party hereto to exercise any right, remedy, power or privilege under this Agreement shall
operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy power or privilege preclude any other or further
exercise of the same or of any other right, remedy, power or privilege, nor shall any waiver of any right, remedy, power or privilege
with respect to any occurrence be construed as a waiver of such right, remedy, power or privilege with respect to any other occurrence.

 

(d) No party shall be deemed to have waived any
claim arising out of this Agreement, or any right, remedy, power or privilege under this Agreement, unless the waiver of such claim, right,
remedy, power or privilege is expressly set forth in a written instrument duly executed and delivered on behalf of such party; and any
such waiver shall not be applicable or have any effect except in the specific instance in which it is given.

 

    6

     

    

 

(e) Any party hereto may unilaterally waive any
of its rights hereunder in a signed writing delivered to the Company.

 

4.4 Further Assurances. The parties
hereto will sign such further documents, cause such meetings to be held, resolutions passed, exercise their votes and do and perform and
cause to be done such further acts and things necessary, proper or advisable in order to give full effect to this Agreement and every
provision hereof. To the fullest extent permitted by Law, the Company shall not directly or indirectly take any action that is intended
to, or would reasonably be expected to result in, the Shareholder Parties being deprived of the rights contemplated by this Agreement.

 

4.5 Assignment. Except as permitted
by Section 3.1(b), no party shall assign, delegate, or otherwise transfer this Agreement or any part hereof without the prior written
consent of the other parties hereto. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the parties
hereto and their respective permitted successors and assigns. Any attempted assignment in violation of the terms of this Section 4.5
shall be null and void, ab initio.

 

4.6 Third Parties. Except as provided
for in this Article IV with respect to any Non-Recourse Party, nothing expressed or implied in this Agreement is intended or shall
be construed to confer upon or give any Person, other than the parties hereto, any right or remedies under or by reason of this Agreement.

 

4.7 Governing Law. This Agreement,
and all claims or causes of action based upon, arising out of, or related to this Agreement, shall be governed by and construed in accordance
with the laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the
State of Delaware or any other jurisdiction) that would cause the application of the law of any jurisdiction other than the State of Delaware.

 

4.8 Jurisdiction; Waiver of Jury Trial.

 

(a) Each of the parties hereto irrevocably and
unconditionally submits to the exclusive jurisdiction of the Chancery Court of the State of Delaware (or, if the Chancery Court of the
State of Delaware declines to accept jurisdiction, any state or federal court sitting in the Borough of Manhattan, State of New York,
New York County), for the purposes of any Proceeding (as defined in the Business Combination Agreement), claim, demand, action or cause
of action (a) arising under this Agreement or (b) in any way connected with or related or incidental to the dealings of the parties hereto
in respect of this Agreement, and irrevocably and unconditionally waives any objection to the laying of venue of any such Proceeding in
any such court, and further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such Proceeding
has been brought in an inconvenient forum. Each party hereby irrevocably and unconditionally waives, and agrees not to assert, by way
of motion or as a defense, counterclaim or otherwise, in any Proceeding, claim, demand, action or cause of action against such Party (i)
arising under this Agreement or (ii) in any way connected with or related or incidental to the dealings of the parties hereto in respect
of this Agreement, (A) any claim that such party is not personally subject to the jurisdiction of the courts as described in this Section
4.8 for any reason, (B) that such party or such party’s property is exempt or immune from the jurisdiction of any such court
or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid
of execution of judgment, execution of judgment or otherwise) and (C) that (x) the Proceeding, claim, demand, action or cause of action
in any such court is brought against such party in an inconvenient forum, (y) the venue of such Proceeding, claim, demand, action or cause
of action against such party is improper or (z) this Agreement, or the subject matter hereof, may not be enforced against such party in
or by such courts. Each party agrees that service of any process, summons, notice or document by registered mail to such party’s
respective address set forth in Section 4.8 shall be effective service of process for any such Proceeding, claim, demand, action
or cause of action.

 

    7

     

    

 

(b) THE PARTIES HERETO EACH HEREBY WAIVES, TO
THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY PROCEEDING, CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (I) ARISING
UNDER THIS AGREEMENT OR UNDER ANY ANCILLARY DOCUMENT OR (II) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE
PARTIES HERETO IN RESPECT OF THIS AGREEMENT, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE.
THE PARTIES HERETO EACH HEREBY AGREES AND CONSENTS THAT ANY SUCH PROCEEDING, CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED
BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES HERETO MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY COURT
AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. EACH PARTY CERTIFIES AND ACKNOWLEDGES
THAT (A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD
NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B) EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS
OF THIS WAIVER, (C) EACH SUCH PARTY MAKES THIS WAIVER VOLUNTARILY AND (D) EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT
BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 4.8.

 

4.9 Specific Performance. The parties
hereto each agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur
in the event that the parties hereto do not perform their obligations under the provisions of this Agreement in accordance with its specified
terms or otherwise breach such provisions. The parties acknowledge and agree that (a) the parties shall be entitled to an injunction,
specific performance, or other equitable relief, to prevent breaches of this Agreement and to enforce specifically the terms and provisions
hereof, without proof of damages, prior to the valid termination of this Agreement, and (b) the right of specific enforcement is an integral
part of the transactions contemplated by this Agreement and without that right, none of the parties would have entered into this Agreement.
Each party agrees that it will not oppose the granting of specific performance and other equitable relief on the basis that the other
parties have an adequate remedy at law or that an award of specific performance is not an appropriate remedy for any reason at law or
equity. The parties hereto each acknowledge and agree that any party seeking an injunction to prevent breaches of this Agreement and to
enforce specifically the terms and provisions of this Agreement in accordance with this Section 4.9 shall not be required to provide
any bond or other security in connection with any such injunction.

 

4.10 Severability. Whenever possible,
each provision of this Agreement will be interpreted in such a manner as to be effective and valid under applicable Law, but if any term
or other provision of this Agreement is held to be invalid, illegal or unenforceable under applicable Law, all other provisions of this
Agreement shall remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is
not affected in any manner materially adverse to any party. Upon such determination that any term or other provision of this Agreement
is invalid, illegal or unenforceable under applicable Law, the parties hereto shall negotiate in good faith to modify this Agreement so
as to effect the original intent of the parties hereto as closely as possible in an acceptable manner in order that the transactions contemplated
hereby are consummated as originally contemplated to the greatest extent possible.

 

    8

     

    

 

4.11 Entire Agreement. This Agreement
constitutes the entire agreement among the parties hereto with respect to the subject matter hereof and supersedes all other prior agreements
and understandings, both written and oral, among the parties hereto with respect to the subject matter hereof. No representations, warranties,
covenants, understandings, agreements, oral or otherwise, with respect to the subject matter contemplated by this Agreement exist between
the parties hereto except as expressly set forth or referenced in this Agreement.

 

4.12 Captions; Counterparts. The
headings, subheadings and captions contained in this Agreement are inserted for convenience only and shall not affect in any way the meaning
or interpretation of this Agreement. This Agreement and any amendment hereto may be executed in one or more counterparts, each of which
shall be deemed to be an original, but all of which shall constitute one and the same agreement. Delivery of an executed counterpart of
a signature page to this Agreement or any amendment hereto by electronic means, including DocuSign, e-mail, or scanned pages shall be
effective as delivery of a manually executed counterpart to this Agreement or any amendment hereto.

 

4.13 Effectiveness; Termination if Business
Combination Agreement is Terminated. This Agreement shall be valid and enforceable as of the date of this Agreement and may not
be revoked by any party hereto; provided that the provisions herein (other than this Article IV) shall not be effective
until the consummation of the Merger. In the event the Business Combination Agreement is terminated in accordance with its terms, this
Agreement shall automatically terminate and be of no further force or effect.

 

4.14 Non-Recourse. This Agreement
may only be enforced against, and any claim or cause of action based upon, arising out of, or related to this Agreement or the transactions
contemplated hereby may only be brought against, the entities that are expressly named as parties hereto, and then only with respect to
the specific obligations set forth herein with respect to such party. Except to the extent a named party to this Agreement (and then only
to the extent of the specific obligations undertaken by such named party in this Agreement), no Non-Recourse Party shall have any liability
(whether in contract, tort, equity or otherwise) for any one or more of the representations, warranties, covenants, agreements or other
obligations or liabilities of the parties to this Agreement or for any claim based on, arising out of, or related to this Agreement or
the transactions contemplated hereby.

 

[Remainder of Page Intentionally Left Blank]

 

    9

     

    

 

IN WITNESS WHEREOF, the parties hereto have executed this Confidentiality
and Lockup Agreement on the day and year first above written.

 

	 	BIOLOG-ID S.A.
	 	 	 
	 	By:	 
	 	 	Name: 	Troy Hilsenroth
	 	 	Title:	Chief Executive Officer

 

	 	GENESIS GROWTH TECH ACQUISITION CORP.
	 	 	 
	 	By:	 
	 	 	Name: 	Eyal Perez
	 	 	Title:	Chief Executive Officer

 

[Signature Page to Confidentiality and Lockup
Agreement]

 

    

     

    

 

IN WITNESS WHEREOF, the parties hereto have executed this Confidentiality
and Lockup Agreement on the day and year first above written.

 

	 	Shareholder Party:
	 	 	 
	 	By:	 
	 	Name: 	      
	 	Title:	 

 

[Signature Page to Confidentiality and Lockup
Agreement]

 

    

     

    

 

Exhibit A 

 

Genesis Growth Tech LLC

Monsieur Jean-Claude Mongrenier

MGR Conseils SARL

La Financière Xerys SCA

La Financière Xerys-2 SCA

La Financière Xerys-3 SCA

La Financière Xerys-4 SCA

La Financière Xerys-5 SCA

La Financière Xerys-6 SCA

La Financière Xerys-8 SCA

La Financière Xerys-9 SCA

La Financière Xerys-13 SCA

Xerys Venture Capital

Xerys Venture Capital 2

Xerys Innovation 1

Xerys Capital Luxembourg

Electro Caloriques SAS

Winus SAS

Monsieur François Luc Monge

Monsieur Antoine Bachoud

Monsieur Yann Campion

Xerys Entreprises

Xerys Developpement SCSP RAIF

Xerys PEA

Xerys Capital France Health

Xerys Capital France Growth

Xerys Capital France Biolog

Xerys Capital France Life

Xerys Capital France Premium

Private Equity RB

Biolog Capdev

Horizon Capdev

Xerys Croissance

La Financière Xerys-21

La Financière Xerys-25

 

    

     

    

 

Exhibit B 

 

FORM OF JOINDER TO CONFIDENTIALITY AND LOCKUP
AGREEMENT 

 

[   ], 20 

 

Reference is made to the Confidentiality and Lockup Agreement, dated
as of [●], 2022, by and among Biolog-id (the “Company”) and the other Shareholder Parties (as defined therein)
from time to time party thereto (as amended from time to time, the “Confidentiality and Lockup Agreement”). Capitalized
terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Confidentiality and Lockup Agreement.

 

Each of the Company and each undersigned holder of ordinary shares
of the Company (each, a “New Shareholder Party”) agrees that this Joinder to the Confidentiality and Lockup Agreement
(this “Joinder”) is being executed and delivered for good and valuable consideration.

 

Each undersigned New Shareholder Party hereby agrees to and does become
party to the Confidentiality and Lockup Agreement as a Shareholder Party. This Joinder shall serve as a counterpart signature page to
the Confidentiality and Lockup Agreement and by executing below each undersigned New Shareholder Party is deemed to have executed the
Confidentiality and Lockup Agreement with the same force and effect as if originally named a party thereto.

 

This Joinder may be executed in multiple counterparts, including by
means of facsimile or electronic signature, each of which shall be deemed an original, but all of which together shall constitute the
same instrument.

 

[Remainder of Page Intentionally Left Blank.]

 

    

     

    

 

IN WITNESS WHEREOF, the undersigned have duly executed this Joinder
as of the date first set forth above.

 

	 	[NEW SHAREHOLDER PARTY]
	 	 	 	 
	 	By:	 
	 	 	Name:	 
	 	 	Title	 
	 	 	 	 
	 	BIOLOG-ID
	 	 	 	 
	 	By:	 
	 	 	Name:	 
	 	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]